Source: International Congress 2018 – New developments in the treatment of asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Y. Adir (Haifa, Israel), M. Castro (St Louis, United States of America), P. Chanez (Marseille, France), M. Mcdonald (Malvern, United States of America), L. Hickey (Malvern, United States of America), M. Garin (Malvern, United States of America). Intravenous (IV) reslizumab efficacy does not differ by blood eosinophil lowering to levels above or below 50 cells/µL. 1031

Member's Comments

No comment yet.

Related content which might interest you: Intravenous (IV) reslizumab improves asthma control, symptoms, and quality of life in patients with historically elevated blood eosinophils Source: International Congress 2018 – Innovative therapies in asthma and COPD Year: 2018 Theophylline drip infusion reduces peripheral blood eosinophil counts and ECP (eosinophil cationic protein) level on acute exacerbation of asthma Source: Eur Respir J 2002; 20: Suppl. 38, 108s Year: 2002 Effects of different serum theophylline concentrations on erythropoietin and hematocrit levels in patients with COPD Source: Eur Respir J 2003; 22: Suppl. 45, 422s Year: 2003 Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Immunomodulatory treatment of severe persistent asthma with interferon-αcon-1 (IFN-αcon-1). Effect on the clinical course of oral corticosteroid dose and eosinophil numbers Source: Annual Congress 2003 - Modulation of bronchial hyperreactivity and immune response in the airways Year: 2003 Consistent efficacy across endpoints with reslizumab despite short term variability in blood eosinophil levels Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018 Exacerbation benefit by blood eosinophil counts with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial: a subgroup analysis Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020 Anti-inflammatory effects of high-dose inhaled fluticasone versus oral prednisone in asthma exacerbations Source: Eur Respir J 2007; 30: 1143-1149 Year: 2007 Rapid switch from epoprostenol (EPO) to intravenous treprostinil (TRE) in patients with pulmonary arterial hypertension (PAH): safety, efficacy, and treatment satisfaction Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009 Oral corticosteroid treatment reduces serum chitotriosidase activity in patients with COPD Source: Annual Congress 2010 - COPD: treatment and monitoring Year: 2010 3 month continuous positive airway pressure (CPAP) therapy decreases serum lipids, but not homocysteine and leptin concentration in patients with OSAS Source: Annual Congress 2009 - Continuous positive airway pressure therapy in obstructive sleep apnoea Year: 2009 One year monitoring of children with bronchial asthma and other allergic diseases treated with inhaled corticosteroids vs cromoglycates with serum ECP (S-ECP), FEV1, total IgE and blood eosinophil count - the influence of different therapy Source: Eur Respir J 2002; 20: Suppl. 38, 432s Year: 2002 Changes in eosinophil count and C reactive protein following treatment with mebendazole in patients with Toxocara-associated asthma Source: Annual Congress 2010 - Treatment and risk factors in lower respiratory tract infections Year: 2010 Sulfidoleukotrienes (sLT) production in vitro by blood leucocytes in asthmatic patients treated with theophylline (T) Source: Eur Respir J 2001; 18: Suppl. 33, 263s Year: 2001 Low doses of inhaled fluticasone propionate induce sputum eosinophil apoptosis and inhibit IL-5 release in naive symptomatic asthmatics (FLIC19) Source: Eur Respir J 2001; 18: Suppl. 33, 336s Year: 2001 Anti-inflammatory effect of montelukast (ML) and inhaled steroids (ICS) on clinical parameters and serum levels of NO in asthmatic children Source: Eur Respir J 2003; 22: Suppl. 45, 132s Year: 2003 Effect of montelukast administration on serum IL-5 and total IgE levels in asthmatics Source: Eur Respir J 2004; 24: Suppl. 48, 579s Year: 2004 Late Breaking Abstract - Blood eosinophil count (EOS) can accurately predict responsiveness to inhaled corticosteroids (ICS) in COPD, but only if measured while patients are not receiving steroids. Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018 Short term reductions in inhaled glucocorticoid doses in children with asthma may be associated with increased levels of serum eosinophil protein X Source: Eur Respir J 2001; 18: Suppl. 33, 451s Year: 2001 Decreased levels of myeloperoxidase in induced sputum of COPD patients after oral glucocorticoids treatment Source: Eur Respir J 2002; 20: Suppl. 38, 404s Year: 2002